SCHEMBL907578

SCHEMBL907578

CNC1CCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6531397 1.00
SCHEMBL6529604 1.00
Hydrochloric Acid SCHEMBL9742278 0.97
SCHEMBL908114 0.79
SCHEMBL907792 0.79
SCHEMBL907881 0.79
Hydrochloric Acid SCHEMBL27906334 0.77
SCHEMBL6521237 0.77
Hydrochloric Acid SCHEMBL29202619 0.77
SCHEMBL907793 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119372649-A Compatible display panel aluminum etching solution, and preparation method and application thereof 浙江奥首材料科技有限公司 2025-01-28 CN claimed
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN claimed
CN-102118969-B Diaminopyridine, diaminopyrimidine and diaminopyridazine modulators of the histamine H4 receptor 詹森药业有限公司 2017-03-08 CN claimed
US-20110053907-A1 SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2011-03-03 US claimed
EP-2276750-A2 SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY Auckland Uniservices Limited (NZ) 2011-01-26 EP claimed
WO-2009120094-A2 SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-10-01 WO claimed
CN-119372649-A Compatible display panel aluminum etching solution, and preparation method and application thereof 浙江奥首材料科技有限公司 2025-01-28 CN disclosed
WO-2024130342-A1 TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS UNIQUEST PTY LIMITED (AU) 2024-06-27 WO disclosed
EP-4223761-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-08-09 EP disclosed
WO-2022251561-A2 SPIROINDOLINONE COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2022-12-01 WO disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN disclosed
EP-2982695-B1 COMPOSITIONS COMPRISING ANTIBODIES TO LINGO OR FRAGMENTS THEREOF BIOGEN MA INC (US) 2019-04-03 EP disclosed
CN-101765587-A 2-azetidinemethanamines and 2-pyrrolidinemethanamines as TAAR ligands HOFFMANN LA ROCHE 2010-06-30 CN disclosed
WO-2009120094-A2 SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-10-01 WO disclosed
US-5616613-A ANTITUMOR AGENTS; ISOMERS; STABLE IN WATER, SOLUBLE FOR INTRAVENOUS INJECTION TORAY INDUSTRIES, INC. (JP) 1997-04-01 US disclosed
EP-0518645-B1 Platinum (II) complex and antitumor agent TORAY INDUSTRIES (JP) 1997-01-15 EP disclosed
EP-0704453-A1 NOVEL PLATINUM (II) COMPLEX AND REMEDY FOR MALIGNANT TUMOR TORAY INDUSTRIES, INC. (JP) 1996-04-03 EP disclosed
US-5348950-A Side effect reduction TORAY INDUSTRIES, INC. (JP) 1994-09-20 US disclosed
EP-0518645-A1 Platinum (II) complex and antitumor agent TORAY INDUSTRIES, INC. (JP) 1992-12-16 EP disclosed